Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
about
Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.How I treat and manage strokes in sickle cell disease.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadCombined chelation therapy with deferasirox and deferoxamine in thalassemia.Physiology and pathophysiology of iron in hemoglobin-associated diseases.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.A complicated disease: what can be done to manage thalassemia major more effectively?Deferasirox for managing iron overload in people with thalassaemia.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Safety profiles of iron chelators in young patients with haemoglobinopathies.How we manage iron overload in sickle cell patients.The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden
P2860
Q34042394-710B0AEC-5132-4CE6-9EC2-F449DC245C02Q35743944-88EE8D99-EA51-465D-88E8-71870E3F565FQ35813192-83B21670-B0FC-414F-BB30-500CFFB9EA66Q36670257-784FD95F-7BFE-4135-B628-3C4C8785F0BBQ37082896-5033B201-9CB4-4185-B28D-F9C241D1E8C9Q38099045-DBB9E256-1306-4051-BA54-5FFCC38B00A2Q38540491-C33D16BA-E87A-43AA-8A99-F26AF2C09754Q38607875-B37550E0-1919-4E47-BC85-57F3D20526A1Q38624033-7F1FC8C9-762A-4CE0-BE4C-F899357A01C0Q38650293-396B940E-7D55-4A85-8552-2B2E983C78BDQ39022073-EF22AB39-7765-4323-B78F-8D39CA4824BAQ39179372-4955093F-14B6-45B4-A2E2-36DF3359BBB8Q39260564-2DF42294-1082-42BA-8BF7-34AF47A5DAF1Q45132809-B54CA76B-1745-4919-9829-FE11A38F6E91Q51040955-5A29790A-CCAF-499F-8A24-B2BE98DC1B57Q55365418-554F6A83-C9A0-4EB6-81EE-E97D28B24394Q56770955-CBC70516-4D40-4CC4-94BB-8C2166CE5456
P2860
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Toward optimizing the use of d ...... combined use with deferoxamine
@ast
Toward optimizing the use of d ...... combined use with deferoxamine
@en
type
label
Toward optimizing the use of d ...... combined use with deferoxamine
@ast
Toward optimizing the use of d ...... combined use with deferoxamine
@en
prefLabel
Toward optimizing the use of d ...... combined use with deferoxamine
@ast
Toward optimizing the use of d ...... combined use with deferoxamine
@en
P2093
P2860
P1433
P1476
Toward optimizing the use of d ...... combined use with deferoxamine
@en
P2093
Carlo Dessi
Dorothy A Kleinert
Patricia J Giardina
Rachel E Randolph
Renzo Galanello
Robert W Grady
P2860
P304
P356
10.3324/HAEMATOL.2012.070607
P577
2012-08-08T00:00:00Z